Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 17, 2016
FDA Continues Site Tours Program
Author(s)Pharmaceutical Technology Editors
The agency is continuing CDER’s Regulatory Project Management Site Tours and Regulatory Interaction Program.
Advertisement
On Feb. 9, 2016, FDA’s Center for Drug Evaluation and Research (CDER) announced the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program, also known as the Site Tours Program. The program is part of CDER’s training and development programs designed to promote high performance and enhance review efficiency by providing firsthand exposure to the industry’s drug development processes.
The Site Tours Program allows small groups of regulatory project managers to observe the manufacturing operations of participating pharmaceutical companies in order to gain more understanding of manufacturing processes. The regulatory project managers also participate in workshops with industry counterparts to learn about a team approach to drug development.
Pharmaceutical companies interested in participating in the program should submit proposed agendas to FDA by April 11, 2016.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement